KR20230093346A - 치료용 덴드리머 - Google Patents

치료용 덴드리머 Download PDF

Info

Publication number
KR20230093346A
KR20230093346A KR1020237019533A KR20237019533A KR20230093346A KR 20230093346 A KR20230093346 A KR 20230093346A KR 1020237019533 A KR1020237019533 A KR 1020237019533A KR 20237019533 A KR20237019533 A KR 20237019533A KR 20230093346 A KR20230093346 A KR 20230093346A
Authority
KR
South Korea
Prior art keywords
formula
dendrimer
pharmaceutically acceptable
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020237019533A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 맥컬
마리앤 버니스 애시포드
이언 그랜트
에드워드 존 헤네시
존 폴 시크리스트
데이비드 오웬
브라이언 켈리
미카엘 야니스
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20230093346A publication Critical patent/KR20230093346A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Prostheses (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020237019533A 2017-02-22 2018-02-22 치료용 덴드리머 Abandoned KR20230093346A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762461983P 2017-02-22 2017-02-22
US62/461,983 2017-02-22
US201762488151P 2017-04-21 2017-04-21
US62/488,151 2017-04-21
US201762591823P 2017-11-29 2017-11-29
US62/591,823 2017-11-29
PCT/EP2018/054420 WO2018154004A1 (en) 2017-02-22 2018-02-22 Therapeutic dendrimers
KR1020197027415A KR102544033B1 (ko) 2017-02-22 2018-02-22 치료용 덴드리머

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197027415A Division KR102544033B1 (ko) 2017-02-22 2018-02-22 치료용 덴드리머

Publications (1)

Publication Number Publication Date
KR20230093346A true KR20230093346A (ko) 2023-06-27

Family

ID=61386833

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197027415A Active KR102544033B1 (ko) 2017-02-22 2018-02-22 치료용 덴드리머
KR1020237019533A Abandoned KR20230093346A (ko) 2017-02-22 2018-02-22 치료용 덴드리머

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020197027415A Active KR102544033B1 (ko) 2017-02-22 2018-02-22 치료용 덴드리머

Country Status (23)

Country Link
US (4) US10314920B2 (enExample)
EP (1) EP3585441A1 (enExample)
JP (1) JP7074761B2 (enExample)
KR (2) KR102544033B1 (enExample)
CN (2) CN110312531A (enExample)
AU (1) AU2018223149B2 (enExample)
BR (1) BR112019016409A2 (enExample)
CA (1) CA3053069A1 (enExample)
CL (1) CL2019002240A1 (enExample)
CO (1) CO2019009722A2 (enExample)
CR (1) CR20190361A (enExample)
DO (1) DOP2019000204A (enExample)
EC (1) ECSP19056271A (enExample)
IL (1) IL268648B (enExample)
JO (1) JOP20190191A1 (enExample)
MX (1) MX2019009442A (enExample)
NI (1) NI201900088A (enExample)
PE (1) PE20191660A1 (enExample)
PH (1) PH12019501896A1 (enExample)
SG (1) SG11201907334QA (enExample)
TW (1) TWI773730B (enExample)
UA (1) UA125655C2 (enExample)
WO (1) WO2018154004A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180326081A1 (en) * 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
JOP20190191A1 (ar) * 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
TWI856967B (zh) 2018-08-17 2024-10-01 瑞典商阿斯特捷利康公司 樹枝狀體配製物
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
SG11202104239XA (en) * 2018-11-20 2021-06-29 Starpharma Pty Ltd Therapeutic dendrimer
US12127496B2 (en) 2019-05-07 2024-10-29 Syddansk Universitet Mechanism for dispensing biological material
KR20220072851A (ko) * 2019-09-26 2022-06-02 스타파마 피티와이 리미티드 치료용 덴드리머
CN115103689A (zh) * 2019-12-04 2022-09-23 阿什瓦塔治疗股份有限公司 用于药物递送的树枝状大分子组合物和方法
IL297531A (en) 2020-04-24 2022-12-01 Ashvattha Therapeutics Inc Dendrimer preparations and methods for treating severe acute respiratory distress syndrome
WO2021213492A1 (zh) * 2020-04-24 2021-10-28 上海森辉医药有限公司 一类载药的大分子及其制备方法
CN115697967B (zh) * 2020-07-10 2024-10-22 江苏恒瑞医药股份有限公司 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用
BR112023002855A2 (pt) * 2020-08-25 2023-04-25 Shanghai Senhui Medicine Co Ltd Macromolécula carregada com fármaco e método de preparação para a mesma
US20230263900A1 (en) * 2020-08-31 2023-08-24 Starpharma Pty Ltd. Dendrimer-drug conjugate

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4410688A (en) * 1981-04-29 1983-10-18 Allied Corporation Macromolecular highly branched homogeneous compound
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
KR101533268B1 (ko) 2005-05-12 2015-07-03 애브비 바하마스 리미티드 아폽토시스 촉진제
ES2625109T3 (es) * 2005-10-25 2017-07-18 Starpharma Pty Limited Compuestos macromoleculares que tienen estequiometría controlada
CN104524596B (zh) * 2006-01-20 2018-10-09 星药股份有限公司 经修饰的大分子
US9127130B2 (en) * 2006-08-11 2015-09-08 Starpharma Pty Ltd. Polylysine dendrimer contrast agent
WO2008017125A1 (en) * 2006-08-11 2008-02-14 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
WO2008061208A2 (en) 2006-11-15 2008-05-22 Genentech, Inc. Arylsulfonamide compounds
US9283302B2 (en) 2011-12-16 2016-03-15 Cormatrix Cardiovascular, Inc. Extracellular matrix encasement structures and methods
WO2009036035A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors
WO2009158668A1 (en) 2008-06-26 2009-12-30 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
US8216549B2 (en) * 2008-07-25 2012-07-10 National Health Research Institutes Method for making a ligand-quantum dot conjugate
EP2376480B1 (en) 2008-12-05 2016-06-01 AbbVie Inc. Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
BR122019016429B1 (pt) 2009-05-26 2020-03-24 Abbvie Ireland Unlimited Company Compostos inibidores da atividade de proteínas bcl-2 antiapoptótica e composição farmacêutica compreendendo ditos compostos
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
WO2011046842A1 (en) * 2009-10-12 2011-04-21 The Regents Of The University Of California Targeted nanoclusters and methods of their use
US8946405B2 (en) 2010-05-05 2015-02-03 Prolynx Llc Controlled release from solid supports
EP2571496A4 (en) 2010-05-05 2016-03-30 Prolynx Llc CONTROLLED RELEASE OF MEDICINE FROM DENIMERS
DK2566335T3 (en) 2010-05-05 2016-10-03 Prolynx Llc Controlled release of active ingredients from macromolecular CONJUGATES
TWI535712B (zh) * 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
ES2834992T3 (es) * 2011-06-06 2021-06-21 Starpharma Pty Ltd Macromoléculas
US20160220689A1 (en) * 2013-09-10 2016-08-04 Starpharma Pty Ltd. Macromolecules of dendrimer-platinum conjugates
EP3152248B1 (en) * 2014-06-06 2019-10-09 Starpharma Pty Ltd Dendrimer-drug conjugates
JOP20190191A1 (ar) * 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
TWI856967B (zh) * 2018-08-17 2024-10-01 瑞典商阿斯特捷利康公司 樹枝狀體配製物
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法

Also Published As

Publication number Publication date
KR102544033B1 (ko) 2023-06-14
US20180264127A1 (en) 2018-09-20
AU2018223149A1 (en) 2019-10-03
US10888624B2 (en) 2021-01-12
WO2018154004A1 (en) 2018-08-30
CA3053069A1 (en) 2018-08-30
SG11201907334QA (en) 2019-09-27
US11717574B2 (en) 2023-08-08
NI201900088A (es) 2020-03-18
TW201841659A (zh) 2018-12-01
CO2019009722A2 (es) 2019-09-18
MX2019009442A (es) 2019-10-09
CN117582521A (zh) 2024-02-23
US20200069810A1 (en) 2020-03-05
IL268648B (en) 2022-04-01
JP2020508985A (ja) 2020-03-26
JOP20190191A1 (ar) 2019-08-08
WO2018154004A9 (en) 2018-12-27
CR20190361A (es) 2019-09-24
DOP2019000204A (es) 2019-08-30
BR112019016409A2 (pt) 2020-04-07
PE20191660A1 (es) 2019-11-11
US20210060172A1 (en) 2021-03-04
IL268648A (en) 2019-10-31
JP7074761B2 (ja) 2022-05-24
TWI773730B (zh) 2022-08-11
ECSP19056271A (es) 2019-08-30
US10314920B2 (en) 2019-06-11
CN110312531A (zh) 2019-10-08
PH12019501896A1 (en) 2019-10-21
UA125655C2 (uk) 2022-05-11
EP3585441A1 (en) 2020-01-01
KR20190112330A (ko) 2019-10-04
CL2019002240A1 (es) 2019-11-29
US20240115716A1 (en) 2024-04-11
AU2018223149B2 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
KR102544033B1 (ko) 치료용 덴드리머
KR102388208B1 (ko) 암을 치료하기 위한 거대 환형 mcl1 억제제
US20100099738A1 (en) Polyethylene glycol lipid conjugates and uses thereof
TW201019963A (en) Polyethylene glycol lipid conjugates and uses thereof
US20100055168A1 (en) Cationic lipids and uses thereof
EA041072B1 (ru) Терапевтические дендримеры
HK40013356A (en) Therapeutic dendrimers
JP5727598B2 (ja) キナーゼ阻害剤の結晶形
CA3020378C (en) Macrocyclic mcl1 inhibitors for treating cancer
HK1262770A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
HK1262770B (en) Macrocyclic mcl1 inhibitors for treating cancer

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PC1904 Unpaid initial registration fee

St.27 status event code: N-2-6-B10-B12-nap-PC1904

St.27 status event code: A-2-2-U10-U14-oth-PC1904